NEW YORK (Reuters Health) Aug 07 - In treatment-naive patients with primary drug-resistant HIV infection who are beginning first-line highly active antiretroviral therapy (HAART), the long-term maintenance of viral suppression is comparable to that of patients infected with wild-type HIV if treatment is guided by genotype testing.

Read the rest of this entry »

MEXICO CITY (Reuters Health) Aug 07 - Male circumcision has a protective effect against HIV, human papilloma virus and trichomonas vaginalis infections, researchers reported at the International AIDS Conference here.

Read the rest of this entry »

WASHINGTON (Reuters) Aug 07 - U.S. efforts to test nearly everyone for HIV have stalled and just 40% of adults in the country have ever been tested, according to a government report on Thursday.

Read the rest of this entry »

NEW YORK (Reuters Health) Aug 07 - Using a delivery method that targets T cells, researchers found that short interfering RNAs, or siRNAs, can markedly suppress HIV-infection in mice with humanized immune systems.

Read the rest of this entry »

August 7, 2008 (Mexico City) — Raltegravir (RAL), the first-in-class integrase inhibitor, continues to provide durable virologic suppression in treatment-naive patients with HIV at 96 weeks when used in combination therapy. The results are similar to what was seen at 48 weeks, according to the latest data presented here at the XVII International AIDS Conference.

Read the rest of this entry »

July 4, 2008 — Data from a preliminary study suggest that recombinant human interleukin (r-hIL)-7 can enhance and broaden immune responses in patients with impaired immunity due to lymphocyte depletion.

Read the rest of this entry »

NEW YORK (Reuters Health) Jul 09 - Early decreases in T-cell activation predict a favorable response to antiretroviral salvage therapy in HIV infection, according to a report in the June 1st Journal of Acquired Immune Deficiency Syndromes.

Read the rest of this entry »

July 9, 2008 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of drug interactions that can increase the risk for serotonin syndrome in patients receiving tramadol HCl, drug interactions between atazanavir sulfate and various agents in the statin drug class, drug interactions with fentanyl, and adverse events associated with improper use of fentanyl patches.

Read the rest of this entry »

NEW YORK (Reuters Health) Jul 11 - HIV-infected patients who do not achieve immunological reconstitution despite viral suppression with highly active antiretroviral therapy (HAART) have defects in bone marrow clonogenic function, according to the results of a study by Italian researchers, published in the June 15th issue of Clinical Infectious Diseases.

Read the rest of this entry »

NEW YORK (Reuters Health) Jul 14 - Patients infected with HIV face an increased risk of developing squamous cell carcinoma of the conjunctiva (SCCC), according to a report in the June 1st issue of the International Journal of Cancer.

Read the rest of this entry »